Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ironwood PharmaceuticalsIRWD -1.32%65 Intrinsic Value: Projected FCF is $9.15 as of Sep. 09, 2026. GuruFocus rates IRWD with a GF Score™ of 65/100 and a GF Value™ of $4.67 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 633 Drug Manufacturers companies, Ironwood Pharmaceuticals ranks better than 91.94% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for Ironwood Pharmaceuticals's Intrinsic Value: Projected FCF or its related term are showing as below:
IRWD'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.1 Med: 1.51 Max: 8.52
Current: 0.45
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Ironwood Pharmaceuticals was 8.52. The lowest was 0.10. And the median was 1.51.
IRWD's Price-to-Projected-FCF is ranked better than 91.94% of 633
companies
in the Drug Manufacturers industry
Industry Median: 1.57
vs IRWD: 0.45
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Ironwood Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
4.115
/
9.1526120570369
=
0.45
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ironwood Pharmaceuticals Intrinsic Value: Projected FCF Related Terms
Ironwood Pharmaceuticals Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Ironwood Pharmaceuticals's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IRWD vs TLRY, AQST, EOLS: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ironwood Pharmaceuticals's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ironwood Pharmaceuticals Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ironwood Pharmaceuticals's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Ironwood Pharmaceuticals's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $9.15 mean?
Ironwood Pharmaceuticals (IRWD) has a Intrinsic Value: Projected FCF of $9.15 as of Sep. 09, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Ironwood Pharmaceuticals and its competitors. According to the industry distribution chart, Ironwood Pharmaceuticals ranks #51 out of 633 companies in the Drug Manufacturers industry, placing it in the top 8.1%.
Is Ironwood Pharmaceuticals' Intrinsic Value: Projected FCF too high?
Ironwood Pharmaceuticals' current Intrinsic Value: Projected FCF is $9.15. The Drug Manufacturers industry median Intrinsic Value: Projected FCF is 1.57. Ironwood Pharmaceuticals' value of $9.15 is 482.8% above this industry median. Based on the distribution chart, Ironwood Pharmaceuticals ranks #51 out of 633 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ironwood Pharmaceuticals has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ironwood Pharmaceuticals' Intrinsic Value: Projected FCF compare to TLRY and AQST?
According to the Drug Manufacturers industry distribution chart, Ironwood Pharmaceuticals ranks #51 out of 633 companies for Intrinsic Value: Projected FCF. This places Ironwood Pharmaceuticals in the top 8% of its industry — outperforming the majority of peers. The industry median Intrinsic Value: Projected FCF is 1.57. Ironwood Pharmaceuticals' value of $9.15 is 482.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.57, based on 633 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ironwood Pharmaceuticals's current Intrinsic Value: Projected FCF of $9.15 is 482.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Ironwood Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ironwood Pharmaceuticals's current Intrinsic Value: Projected FCF is $9.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ironwood Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ironwood Pharmaceuticals (IRWD) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.67, compared to a current price of $4.12 — trading 11.9% below its estimated fair value. The current Intrinsic Value: Projected FCF is $9.15 and 482.8% above the Drug Manufacturers industry median of 1.57. Ironwood Pharmaceuticals' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Ironwood Pharmaceuticals (IRWD), the current Intrinsic Value: Projected FCF is $9.15 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ironwood Pharmaceuticals (IRWD) Overvalued in 2026?
Based on GuruFocus' analysis, Ironwood Pharmaceuticals stock appears to be undervalued.
The current stock price of $4.12 is trading 11.9% below its estimated GF Value™ of $4.67.
GuruFocus considers Ironwood Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for IRWD:
Intrinsic Value: Projected FCF: $9.15
GF Value™: $4.67 vs. price of $4.12 (11.9% below fair value)
Industry Position: 482.8% above the Drug Manufacturers median (#51 of 633)
No single metric tells the full story. See the IRWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
65GF Score
Get the complete analysis for IRWD
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRWD has been successfully added to your 
